Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 18 Jan 2018

France Gets Ready to Test CAR-Treg Cells to Avoid Transplant Rejection

TxCell has received a €1.2 loan from Bpifrance to complete preclinical trials with its CAR-Treg technology for transplant rejection and start human testing. French biotech TxCell is finalizing the preparations to take its first cell therapy to clinical trials. The treatment, called HLA-A2 CAR-Treg, is intended for the prevention of chronic rejection after organ transplantation. […]

January 18, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 18 Jan 2018

First Patient Successfully Implanted with Heart Valve Replacement Device

French company Kephalios has successfully implanted a new adjustable device to repair a heart valve defect in a human patient for the first time. The first of five patients in a clinical trial at the Vienna General Hospital has received an implant designed to repair mitral valve regurgitation. This disease causes the mitral valve to not close properly […]

January 18, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

owkin artificial intelligence drug development

More News! 17 Jan 2018

€9M Round for AI Algorithms to Speed up Drug Development

Owkin has raised $11M(€9M) in a Series A round to fund its artificial intelligence platform for medical research and drug discovery. Owkin, based in New York and Paris, was founded in 2016 to develop machine learning algorithms that can deal with the overabundance of information in biology to optimize the drug development process. The company […]

January 17, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2018

Oxford Firm Recruits Two Partners to Build Drug Discovery AI

e-Therapeutics has teamed up with AI experts Intellegens and Biorelate to improve its technology for computer-based drug discovery. Based in Oxford, e-Therapeutics has the mission of reducing the time and money it costs to develop new drugs with the help of artificial intelligence. Its platform can explore large amounts of public and private databases to […]

January 16, 2018 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 16 Jan 2018

Dutch Biotech Joins International Effort to Eradicate Polio

Batavia Biosciences joins an international consortium to develop and manufacture a safer type of polio vaccine. Their ultimate goal is to eradicate the disease. Based in Leiden, the Netherlands, Batavia Biosciences specializes in the development and production of viruses and proteins. Its expertise has attracted an international consortium to recruit Batavia in their effort to […]

January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Jan 2018

Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine

Vaccitech has closed a Series A fundraising that will support clinical trials with its vaccine technology against influenza and prostate cancer. Spun out from Oxford University in 2016, Vaccitech has now closed its Series A fundraising round. Amounting to a total of £20M (€22.5M), the round was co-led by GV, Oxford Sciences Innovation and Sequoia China, and joined […]

January 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 13 Jan 2018

Mars Astronauts Might Wear Spacesuits Made of Fungi

A team of biodesigners is getting us ready to live on Mars by creating the clothes that future Martians will use using fungi to create the materials. Science fiction has been preparing us for the colonization of Mars for over a century. Many see the planet as an alternative home for when we destroy or overcrowd […]

January 13, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

gensight retinitis pigmentosa gene therapy

News and Trends 10 Jan 2018

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

GenSight will start a clinical trial in the UK testing a combination of gene therapy and a wearable device to restore sight in patients with retinitis pigmentosa. The UK Medicines and Healthcare Regulatory Agency (MHRA) has accepted GenSight’s application to run a first clinical trial in the UK testing a new type of therapy with the […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Infographics 10 Jan 2018

Infographic: All You Need to Know About Checkpoint Inhibitors

Everything you need to know about what checkpoint inhibitors are and why they have caused a wave of hype for cancer immunotherapies. Since the approval of the first PD-1 checkpoint inhibitor, Keytruda, in 2014, there has been an explosion of the numbers of trials testing these drugs, both alone and in combination. The latest figure, […]

January 10, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

More News! 9 Jan 2018

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […]

January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jan 2018

Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA

Galapagos and ProQR will work together to target fibrosis using a technology to treat genetic diseases without permanent changes to the DNA. A new research collaboration between two biotech companies in Leiden, the Netherlands, will aim to discover a new class of drugs to treat fibrosis — a process of excessive scarring that leads to […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 Jan 2018

Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis

TopiVert has successfully completed a Phase I trial in ulcerative colitis with a new class of drug that could help reduce adverse side effects. The results of a Phase I trial run by London-based biotech TopiVert have shown potential for a new type of therapy for ulcerative colitis. The study revealed that the drug, called […]

January 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Clara Rodríguez Fernández

About

Articles by Clara Rodríguez Fernández

France Gets Ready to Test CAR-Treg Cells to Avoid Transplant Rejection

First Patient Successfully Implanted with Heart Valve Replacement Device

€9M Round for AI Algorithms to Speed up Drug Development

Oxford Firm Recruits Two Partners to Build Drug Discovery AI

Dutch Biotech Joins International Effort to Eradicate Polio

Young Oxford Biotech Raises €22.5M to Develop a Universal Flu Vaccine

Mars Astronauts Might Wear Spacesuits Made of Fungi

French Biotech Starts Trials to Restore Sight in All Types of Retinitis Pigmentosa

Infographic: All You Need to Know About Checkpoint Inhibitors

Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk

Galapagos Teams up with Dutch Biotech to Edit Fibrosis out of our RNA

Biotech in London Paves the Way for a New Therapy for Ulcerative Colitis

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

About

Articles by Clara Rodríguez Fernández

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!